ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101 - Summary - MDSpire

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

Share

Objective:

To evaluate the outcomes of testosterone suppression combined with androgen receptor pathway inhibitors in patients.

Approach:
  • Study Design: The A-DREAM/Alliance A032101 study was presented by Dr. Atish Choudhury from Dana-Farber Cancer Institute.
Key Findings:
  • 41% of favorable responders remained treatment-free after testosterone suppression plus androgen receptor pathway inhibitor.
  • Testosterone recovery was observed at 18 months following treatment interruption.
Interpretation:

Conclusion:

Original Source(s)

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

  • July 1, 2026

Related Content

Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report

Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target